AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24911173 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (attention to somatic arousal)
Number of subjects: 33
Study 24911173 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (distraction from somatic arousal)
Number of subjects: 33
Study 24911173 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (no distractions or interoceptive prompts)
Number of subjects: 33
Study 24911173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary biking)
Number of subjects: 33
Study 23471268 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK249320 (1, 5, or 15 mg/kg per infusion)
Number of subjects: 42
Study 23471268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21724317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device LUCAS
Number of subjects: 21
Study 21724317 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 21
Study 18091023 — intervention group
Group type: EXPERIMENTAL
Intervention: rs17036314
Number of subjects: 479
Study 18091023 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1801282 (Pro12Ala)
Number of subjects: 479
Study 18091023 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in physical activity (PA)
Number of subjects: 479
Study 18091023 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1152003
Number of subjects: 479
Study 16855077 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 20
Study 16855077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14614791 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective processing task (modified Stroop)
Number of subjects: 47
Study 10752681 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of adjuvant tamoxifen
Number of subjects: 0
Study 10752681 — intervention group
Group type: COMPARATOR
Intervention: 2 years of adjuvant tamoxifen
Number of subjects: 0
Study 10752681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged tamoxifen therapy
Number of subjects: 0
Study 10752681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 0
Study 8855856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate (650 mg twice daily)
Number of subjects: 81
Study 8855856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 1387604 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-containing ipratropium bromide
Number of subjects: 50
Study 1387604 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free ipratropium bromide
Number of subjects: 50
Study 1387604 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 7 preservative-free ipratropium bromide
Number of subjects: 50
Study 1387604 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 50
Study 6828092 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenously initially, then 200 mg daily for three months)
Number of subjects: 1395
Study 6828092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (697 patients)
Number of subjects: 1395
Study 6828092 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study 6828092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 30565397 — intervention group
Group type: EXPERIMENTAL
Intervention: FIREHAWK sirolimus-eluting stent
Number of subjects: 1007
Study 29678619 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 83
Study 29678619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 27310103 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost
Number of subjects: 30
Study 27310103 — intervention group
Group type: COMPARATOR
Intervention: Preserved latanoprost
Number of subjects: 30
Study 25695295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled colistin/oral ciprofloxacin
Number of subjects: 40
Study 25695295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin 300 mg/oral ciprofloxacin
Number of subjects: 40
Study 25695295 — intervention group
Group type: COMPARATOR
Intervention: Control group (chronically colonized patients)
Number of subjects: 40
Study 22110163 — intervention group
Group type: EXPERIMENTAL
Intervention: AM211 200 mg once daily for 7 days
Number of subjects: 0
Study 22110163 — intervention group
Group type: EXPERIMENTAL
Intervention: AM211 (various doses 100 to 600 mg)
Number of subjects: 0
Study 22110163 — intervention group
Group type: EXPERIMENTAL
Intervention: AM211 (multiple dosing)
Number of subjects: 0
Study 22110163 — intervention group
Group type: EXPERIMENTAL
Intervention: AM211 (all doses)
Number of subjects: 0
Study 20889993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (25 μg/kg) in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Number of subjects: 648
Study 20889993 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Number of subjects: 648
Study 20889993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (25 μg/kg).
Number of subjects: 648
Study 20889993 — intervention group
Group type: EXPERIMENTAL
Intervention: PFA-100 (both cartridges).
Number of subjects: 648
Study 17846979 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% calorie restricted diet over 12 weeks
Number of subjects: 25
Study 15103594 — intervention group
Group type: COMPARATOR
Intervention: NIR stent
Number of subjects: 603
Study 15103594 — intervention group
Group type: EXPERIMENTAL
Intervention: NIROYAL stent
Number of subjects: 603
Study 11665396 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Flurbiprofen gel
Number of subjects: 16
Study 11665396 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Triclosan gel
Number of subjects: 16
Study 9678314 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon4/4 genotype
Number of subjects: 1131
Study 9678314 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon3/4 genotype
Number of subjects: 1131
Study 9678314 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon4 allele
Number of subjects: 1131
Study 9678314 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotypes
Number of subjects: 1131
Study 7991885 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms via metered dose inhaler, twice daily for 2 weeks)
Number of subjects: 141
Study 7991885 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (individually dose‐titrated, twice daily for 2 weeks)
Number of subjects: 141
Study 2643845 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 to 160 mg daily)
Number of subjects: 16
Study 2643845 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (320 mg daily)
Number of subjects: 16
Study 2643845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29324576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest (VG) during recovery periods within a training session (8 bouts of 5-minute fighting with 5-minute rest) and up to 10 minutes after the session
Number of subjects: 16
Study 29324576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest (VG)
Number of subjects: 16
Study 29324576 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without cooling aids
Number of subjects: 16
Study 28595341 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Number of subjects: 31
Study 25686323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge-preservation procedure with Bio‐Oss® and Bio‐Gide® (RP)
Number of subjects: 16
Study 25686323 — intervention group
Group type: COMPARATOR
Intervention: Extraction alone (EXT)
Number of subjects: 16
Study 23608924 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted debriefing
Number of subjects: 387
Study 23608924 — intervention group
Group type: COMPARATOR
Intervention: Nonscripted debriefing
Number of subjects: 387
Study 21736494 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month aerobic regular exercise (moderate-intensity power walking)
Number of subjects: 60
Study 21736494 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (sedentary)
Number of subjects: 60
Study 20109380 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrastin lymph‐draining cream with elastocompressive therapy
Number of subjects: 80
Study 20109380 — intervention group
Group type: COMPARATOR
Intervention: Elastocompressive therapy only
Number of subjects: 80
Study 16677228 — intervention group
Group type: EXPERIMENTAL
Intervention: Northern sites
Number of subjects: 1000
Study 16677228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar II patients
Number of subjects: 1000
Study 16677228 — intervention group
Group type: COMPARATOR
Intervention: Southern sites
Number of subjects: 1000
Study 12727154 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved left ventricular systolic function
Number of subjects: 5491
Study 12727154 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced left ventricular systolic function
Number of subjects: 5491
Study 12727154 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with ischemic heart disease
Number of subjects: 5491
Study 12727154 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 5491
Study 10809036 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat, 120 mg 3 times a day for 104 weeks
Number of subjects: 675
Study 10809036 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times a day for 104 weeks
Number of subjects: 675
Study 8614396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT) with lomustine (CCNU), vincristine, and prednisone for 1 year
Number of subjects: 36
Study 8614396 — intervention group
Group type: COMPARATOR
Intervention: Cranio-spinal irradiation (CSI) alone
Number of subjects: 36
Study 1600529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone at 300 mg twice daily
Number of subjects: 200
Study 1600529 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinidine retard 250 mg twice daily
Number of subjects: 200
Study 1600529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 200
Study 1600529 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinidine
Number of subjects: 200
Study 3904258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms ml‐1 hepatitis B vaccine
Number of subjects: 98
Study 3904258 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms ml‐1 hepatitis B vaccine
Number of subjects: 98
Study 29557709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Number of subjects: 0
Study 29958034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient detoxification supplement (1,350 mg/serving)
Number of subjects: 22
Study 29958034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28662266 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 28662266 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 26432552 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (n = 179)
Number of subjects: 357
Study 26432552 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures (n = 178)
Number of subjects: 357
Study 26432552 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 357
Study 23400916 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute infusion of ertapenem 1 g
Number of subjects: 12
Study 23400916 — intervention group
Group type: COMPARATOR
Intervention: 30-minute infusion of ertapenem 1 g
Number of subjects: 12
Study 20091057 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 20
Study 19837318 — intervention group
Group type: EXPERIMENTAL
Intervention: PES split crest implants
Number of subjects: 86
Study 19837318 — intervention group
Group type: COMPARATOR
Intervention: unsplit alveolar ridge implants
Number of subjects: 86
Study 17023212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n=12), received once a week for 10 weeks
Number of subjects: 36
Study 17023212 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (n=12), needle insertion in non-acupoints, received once a week for 10 weeks
Number of subjects: 36
Study 17023212 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12), receiving no treatment
Number of subjects: 36
Study 14995941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Recruitment Maneuver (LRM) - four 10‐s insufflations to an airway pressure of 45 cmH2O
Number of subjects: 30
Study 14995941 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 12 cmH2O
Number of subjects: 30
Study 14995941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Recruitment Maneuver + PEEP 12 cmH2O
Number of subjects: 30
Study 11240413 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 11240413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9825375 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Fr electrode catheters
Number of subjects: 205
Study 9825375 — intervention group
Group type: COMPARATOR
Intervention: 6 Fr electrode catheters
Number of subjects: 205
Study 7719108 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of hyoscyamus, self made Retarded Recovery Pill and acupuncture
Number of subjects: 80
Study 7719108 — intervention group
Group type: COMPARATOR
Intervention: Nao An Tai, Nao Fu Kang (Control)
Number of subjects: 80
Study 7719108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of traditional Chinese and Western medicine
Number of subjects: 80
Study 2643074 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 tablets of 4 mg each)
Number of subjects: 40
Study 2643074 — intervention group
Group type: COMPARATOR
Intervention: Dextrose placebo (identical in appearance, same dosage schedule)
Number of subjects: 40
Study 4553613 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 380
Study 4553613 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 380
Study 31883336 — intervention group
Group type: EXPERIMENTAL
Intervention: WebQuit Plus (ACT-based intervention)
Number of subjects: 51
Study 31883336 — intervention group
Group type: COMPARATOR
Intervention: Smokefree.gov (control)
Number of subjects: 51
Study 31405866 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g) plus piperaquine (960 mg) for three days
Number of subjects: 122
Study 31405866 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (4,500 mg sulfadoxine plus 225 mg pyrimethamine, single dose)
Number of subjects: 122
Study 31405866 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus piperaquine
Number of subjects: 122
Study 31405866 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 122
Study 29017627 — intervention group
Group type: COMPARATOR
Intervention: 20 g milk protein (MLK20)
Number of subjects: 12
Study 29017627 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g mycoprotein (MYC20)
Number of subjects: 12
Study 29017627 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g mycoprotein (MYC40)
Number of subjects: 12
Study 29017627 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g mycoprotein (MYC60)
Number of subjects: 12
Study 29017627 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g mycoprotein (MYC80)
Number of subjects: 12
Study 25622774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading, 90 mg twice daily for maintenance dose)
Number of subjects: 25
Study 25622774 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading, 75 mg once daily for maintenance dose)
Number of subjects: 25
Study 25622774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 25
Study 23179117 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.25% alone on the brachial plexus nerve (Group A)
Number of subjects: 150
Study 23179117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% with 20 mg parecoxib locally on the nerve block (Group B)
Number of subjects: 150
Study 23179117 — intervention group
Group type: COMPARATOR
Intervention: 20 mg parecoxib intravenously (Group C)
Number of subjects: 150
Study 21351829 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal doses of 20 Gy delivered by the X‐knife unit 16 days postimplantation
Number of subjects: 25
Study 21351829 — intervention group
Group type: COMPARATOR
Intervention: Tumor group (control)
Number of subjects: 25
Study 19114383 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke|Quit
Number of subjects: 216
Study 19114383 — intervention group
Group type: COMPARATOR
Intervention: Canadian Cancer Society's self-help program
Number of subjects: 216
Study 19114383 — intervention group
Group type: COMPARATOR
Intervention: Usual care quit kit
Number of subjects: 216
Study 19114383 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 216
Study 16995861 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via pMDI + Volumatic
Number of subjects: 18
Study 16995861 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via pMDI + Volumatic
Number of subjects: 18
Study 16995861 — intervention group
Group type: COMPARATOR
Intervention: 558 microg salbutamol via Diskus
Number of subjects: 18
Study 16995861 — intervention group
Group type: COMPARATOR
Intervention: 395 microg salbutamol via Diskus
Number of subjects: 18
Study 16995861 — intervention group
Group type: COMPARATOR
Intervention: 404 microg salbutamol via Diskus
Number of subjects: 18
Study 15560538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg daily)
Number of subjects: 30
Study 15560538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11129616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (70 micrograms.kg‐1)
Number of subjects: 30
Study 11129616 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 9285655 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of ramipril (24 hours after AMI)
Number of subjects: 309
Study 9285655 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of ramipril (14 days after AMI)
Number of subjects: 309
Study 9285655 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after AMI
Number of subjects: 309
Study 9285655 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with thrombus
Number of subjects: 309
Study 9285655 — intervention group
Group type: EXPERIMENTAL
Intervention: LV size
Number of subjects: 309
Study 8367518 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained least-squares restoration (CLSR) technique
Number of subjects: 70
Study 8367518 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on renography parameters (excretion ratio, rate of uptake, time to peak activity)
Number of subjects: 70
Study 6761832 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 50 micrograms in each nostril twice daily
Number of subjects: 47
Study 6761832 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 50 micrograms in each nostril four times daily
Number of subjects: 47
Study 31747663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ)
Number of subjects: 25
Study 31747663 — intervention group
Group type: COMPARATOR
Intervention: Normal eyes (control group)
Number of subjects: 25
Study 31348973 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive feeding style (adapting feeding pace to spoonful weight)
Number of subjects: 38
Study 31348973 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants' appetitive traits (food responsiveness)
Number of subjects: 38
Study 28454194 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (arthroscopy of the shoulder)
Number of subjects: 86
Study 28454194 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (physiotherapy under physician control)
Number of subjects: 86
Study 25875938 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy (3 sessions, 60 minutes each)
Number of subjects: 62
Study 25875938 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 62
Study 24332581 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT (external beam whole breast radiotherapy)
Number of subjects: 141
Study 24332581 — intervention group
Group type: COMPARATOR
Intervention: IORT (intraoperative radiotherapy)
Number of subjects: 141
Study 22997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate bars (35% fat)
Number of subjects: 8
Study 22997185 — intervention group
Group type: COMPARATOR
Intervention: Chocolate dessert (8% fat)
Number of subjects: 8
Study 19204263 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg p.o. with interferon beta‐1a
Number of subjects: 313
Study 19204263 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (IVMP) 1,000 mg/day for 3 days bimonthly with interferon beta‐1a
Number of subjects: 313
Study 19204263 — intervention group
Group type: COMPARATOR
Intervention: Placebo with interferon beta‐1a
Number of subjects: 313
Study 17324291 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck manipulation
Number of subjects: 182
Study 17324291 — intervention group
Group type: COMPARATOR
Intervention: Neck mobilisation
Number of subjects: 182
Study 16098943 — intervention group
Group type: EXPERIMENTAL
Intervention: Corpus-based measures of word semantics
Number of subjects: 0
Study 16098943 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual world paradigm
Number of subjects: 0
Study 14553868 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guideline implemented using a multifaceted strategy
Number of subjects: 608
Study 14553868 — intervention group
Group type: COMPARATOR
Intervention: Practice guideline alone (control arm)
Number of subjects: 608
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD: 34.3% total fat, 15.0% saturated fat)
Number of subjects: 103
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step I diet (28.6% total fat, 9.0% saturated fat)
Number of subjects: 103